Phase III, Multicenter, Double-Blind, Randomized Study of Letrozole, an Aromatase Inhibitor, for Advanced Breast Cancer Versus Megestrol Acetate

This publication has 22 references indexed in Scilit:

• Letrozole: Updated Duration of Response
  Journal of Clinical Oncology, 1999
• 643: Letrozole (FEMARA®), a new potent, selective aromatase inhibitor (AI): Superior to another AI, aminoglutethimlde (AG), in postmenopausal women with advanced breast cancer (ABC), after relapse or progression on previous anti-estrogen therapy
  European Journal Of Cancer, 1997
• Formestane
  Drugs & Aging, 1996
• A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer *
  European Journal Of Cancer, 1996
• Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women
  Journal of Clinical Endocrinology & Metabolism, 1993
• Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects.
  Journal of Clinical Endocrinology & Metabolism, 1993
• Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects
  Journal of Clinical Endocrinology & Metabolism, 1993
• The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer
  The Journal of Steroid Biochemistry and Molecular Biology, 1993
• Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor
  The Journal of Steroid Biochemistry and Molecular Biology, 1990
• Endocrine Therapy of Advanced Breast Cancer
  Acta Oncologica, 1988